Search
SOLACI Congress
HomeAHA 2017Highlights

Highlights

View Category
Highlights

CANTOS: Less Cardiovascular Events with Canakinumab

A new analysis from the CANTOS trial shows that individuals who initially respond to canakinumab benefit the...
solaci -
Learn More
Antiplatelet

DACAB: Ticagrelor and Aspirin Improve Vein Graft Patency

According to this Chinese study, dual antiplatelet therapy with ticagrelor and aspirin improves vein graft patency a year after surgery without increasing the...
solaci -
Learn More
Highlights

New High Blood Pressure Guidelines

The wait is finally over: the high blood pressure guidelines that have been in the works for...
solaci -
Learn More
Coronary disease

PRESERVE: IV Bicarbonate and Oral N-Acetylcysteine Do Not Prevent Contrast-Associated Acute Kidney Injury

Use of IV bicarbonate instead of saline and administration of oral N-acetylcysteine are not effective strategies for...
solaci -
Learn More
Acute coronary syndromes

NCDR ACTION Registry: Anticoagulated Patients with No Higher Risk of Bleeding in Emergency Procedures

Patients with a history of atrial fibrillation treated with warfarin or any of the new direct oral anticoagulants undergoing...
solaci -
Learn More
Highlights

FOURIER: Evolocumab Found Beneficial for Patients with Peripheral Vascular Disease of Prior MI

Patients with peripheral vascular disease or prior acute myocardial infarction (especially within the first two years after the event)...
solaci -
Learn More
Chronic Ischemic cardiopathy

TRICS III: Restrictive Transfusion Was Noninferior to Liberal Use in Patients Who Undergo Cardiac Surgery

A large study conducted in 19 countries has found that a policy of restrictive red-cell transfusion during cardiac...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

Dr. Carlos Fava - 0
This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Dr. Omar Tupayachi - 0
Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

Institutional News

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy